following a resubmission assessed under the end of life process:
tepotinib (Tepmetko®) is accepted for use within NHSScotland.
Indication under review: For the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.
In a phase II single-arm study in adults with advanced NSCLC with METex14 skipping mutations, tepotinib was associated with an objective response rate of 51%.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice931KB (PDF)
Medicine details
- Medicine name:
- tepotinib (Tepmetko)
- SMC ID:
- SMC2535
- Indication:
For treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.
- Pharmaceutical company
- Merck Serono Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 16 January 2023